learn2.peerview.com Open in urlscan Pro
84.207.240.87  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS CONTENT WAS DESIGNED FOR
PORTRAIT ORIENTATION ONLY.



   
 * Get Credit


CME/MOC Information Get Credit Practice Aids SlidesPodcastsAbbr.ShareFeedback
1.0 CME/MOCThis activity expired on July 08, 2022; credit is no longer
available.
Gaining New Ground With Immunotherapy in the Management of Early and Advanced
Gastrointestinal Cancers: Translating Progress Into Clinical Practice in
Gastric, Esophageal, GEJ, and Colorectal Cancers

Co-Chair & Presenter
Jaffer A. Ajani, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Co-Chair & Presenter
Ian Chau, MD, FRCP
The Royal Marsden Hospital
London and Surrey, United Kingdom
Chapter ContentActivity Chapters

Please complete and tap Submit at the end to continue.

Question 1/5
Your patient is a 62-year-old man presenting with metastatic adenocarcinoma
(assume CT scan showed two liver lesions, a large gastro-hepatic nodal mass, and
thickened GEJ). His cancer was HER2 negative with PD-L1 CPS = 7, MSS, TMB = 5,
KRAS amplification, and TP53 mutation. He is in otherwise good health with no
major comorbidities. How would you manage this patient?
   
   
 * Chemotherapy with platinum + fluoropyrimidine
   
   
   
 * Chemotherapy with platinum/fluoropyrimidine/taxane + trastuzumab
   
   
   
 * Single-agent PD-1 therapy (nivolumab or pembrolizumab)
   
   
   
 * Chemotherapy with platinum + fluoropyrimidine + nivolumab
   
   
   
 * I’m not sure
   
   

Question 2/5
Which of the following statements accurately summarizes phase 3 RATIONALE 302
trial evidence on survival outcomes with the use of tislelizumab versus
chemotherapy in patients with previously treated advanced/metastatic ESCC?
   
   
 * No OS improvement with tislelizumab has been reported to date
   
   
   
 * Significant improvement in OS in the ITT population
   
   
   
 * Significant improvement in OS only in patients with vCPS ≥10%
   
   
   
 * Significant improvement in OS, but only in Asian patients
   
   
   
 * I’m not sure
   
   

Question 3/5
Which of the following statements summarizes the main outcomes from the phase 3
CheckMate -648 trial, testing nivolumab combined with chemotherapy or ipilimumab
versus chemotherapy as first-line therapy in patients with advanced/metastatic
ESCC?
   
   
 * OS was significantly improved with nivolumab + chemotherapy but not with
   nivolumab + ipilimumab
   
   
   
 * OS was significantly improved with nivolumab + ipilimumab but not with
   nivolumab + chemotherapy
   
   
   
 * OS was significantly improved with nivolumab + chemotherapy or ipilimumab
   compared with chemotherapy
   
   
   
 * The nivolumab-containing arms only improved OS only in patients with ESCC
   showing very high PD-L1 expression (≥10%)
   
   
   
 * I’m not sure
   
   

Question 4/5
A patient with obstructive T3N1M0 distal esophageal adenocarcinoma received
neoadjuvant CRT followed by esophagectomy. At a multidisciplinary team meeting
after the surgery, your surgical oncology colleague reports the presence of
residual pathologic disease. In the context of team-based care, what would you
do as the next step for this patient?
   
   
 * Active surveillance
   
   
   
 * Adjuvant chemotherapy
   
   
   
 * Adjuvant CRT
   
   
   
 * Adjuvant nivolumab
   
   
   
 * I’m not sure
   
   

Question 5/5
You are considering treatment options for your 61-year-old male patient with
newly diagnosed, HER2-positive metastatic gastric cancer. He has good
performance status (ECOG score = 0) with no major comorbidities. Based on recent
evidence, how would you manage this patient?
   
   
 * Pembrolizumab + trastuzumab + 5-fluorouracil and cisplatin (FP) or
   capecitabine and oxaliplatin (CAPOX)
   
   
   
 * Pembrolizumab + trastuzumab
   
   
   
 * Trastuzumab + FP or CAPOX
   
   
   
 * FP or CAPOX
   
   
   
 * I’m not sure
   
   

Submit


ACTIVITY CHAPTERS

PRE-TEST



THE CLINICAL EXPERIENCE WITH IMMUNE CHECKPOINT INHIBITORS IN COLORECTAL CANCER -
12:17



FUTURE DIRECTIONS IN THE MANAGEMENT OF CRC - 1:36



RESHAPING THE TREATMENT ALGORITHM FOR ADVANCED/METASTATIC GASTRIC, GEJ, AND
ESOPHAGEAL CANCERS WITH IMMUNOTHERAPY - 20:07



CHECKPOINT INHIBITION IN ESOPHAGEAL CANCER - 14:35



THE CLINICAL EXPERIENCE WITH IMMUNOTHERAPY IN EARLY-STAGE GASTRIC, GEJ, AND
ESOPHAGEAL CANCERS - 15:45



GET CREDIT




SEE MORE EDUCATION FROM PEERVIEW IN ONCOLOGY


CONNECT WITH US




Copyright © 2000-2021, PeerView
Terms of Use | Privacy Policy | Sign Up for Email Alerts